Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...

In a turbulent market environment, Moderna Inc (BMV:MRNA). shares have touched a 52-week low, sinking to $30.7, with concerning financial metrics showing negative EBITDA of $2.36 billion and gross ...

Janney Montgomery Scott LLC lowered its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 21.0% in the fourth quarter, ...

RNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman ...

Shares of vaccine companies such as Moderna (MRNA), Pfizer (PFE) and BioNTech (BNTX), among others, are falling after a ...

Moderna (MRNA) closed at $34.45 in the latest trading ... Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future.

If an investor was to purchase shares of MRNA stock at the current price level of $37.60/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock ...

The analyst cut her price target on MRNA to $51 from $99 ... which MRNA is developing in partnership with Merck (MRK), to lift MRNA stock this year. Ellison’s Statement on Potential Cancer ...